Background: Bapineuzumab, a humanized anti-amyloid-beta (A␤) monoclonal antibody for the po-
veloped in 6% of patients, 8 likely due to a proinflammatory T-cell response against the A␤ peptide. 9 One potential means of eliminating the proinflammatory T-cell response is by passively infusing anti-A␤ antibodies. Bapineuzumab, an antibody targeted against the N-terminus of A␤, is a passive A␤ immunotherapy being tested for AD. Bapineuzumab is hypothesized to bind to A␤ in the brain and facilitate its removal, yielding beneficial clinical effects. A phase 1 study with bapineuzumab determined a half-life of 24 days (unpublished data), leading to phase 2 dosing every 13 weeks. The current multiple ascending dose study was initially designed and powered to evaluate the safety of bapineuzumab within individual dose cohorts. Although the study design remained unchanged, the protocol was amended to evaluate efficacy as the primary objective based partly on preliminary results from the phase 1 study. It was recognized that the small cohorts in this study would provide sufficient power to detect only very large treatment differences; however, if successful, the urgency of delivering an effective treatment to patients with AD argued for making efficacy the primary outcome. Patients. Eligible patients were aged 50 to 85 years inclusive, met criteria for probable AD, 10 and had an MRI consistent with AD. Additional inclusion criteria were a Mini-Mental State Examination (MMSE) score of 16 -26 11 and a Rosen Modified Hachinski Ischemic score Յ4. 12 Patients were excluded for clinically significant neurologic disease other than AD; a major psychiatric disorder, history of stroke or seizures, a Hamilton Rating Scale score for Depression Ͼ12 13 ; current anticonvulsant, antiparkinsonian, anticoagulant, or narcotic medications; recent immunosuppressive or cancer chemotherapy medications; or cognitive enhancers other than acetylcholinesterase inhibitors or memantine at a stable dose for at least 120 days before screening.
Standard protocol approvals, registrations, and patient consents. The study (ClinicalTrials.gov number NCT00112073) was approved by each site's local institutional review board, and written informed consent was obtained from each patient (or legally authorized representative).
Study design and treatment.
A total of 234 patients were randomly assigned to receive either IV bapineuzumab or placebo, in an 8:7 ratio, in 1 of 4 sequential dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Adaptive stratified randomization was used to achieve a balance of baseline acetylcholinesterase inhibitor or memantine use and screening MMSE score (low ϭ 16 -21 vs high ϭ 22-26). Patients received study drug as a 1-hour IV infusion every 13 weeks for 6 infusions during the 18-month study. An independent Safety Monitoring Committee (SMC) assessed the safety of treatment throughout the trial. The 0.5 mg/kg dose cohort was first to enroll. The 0.15 mg/kg dose cohort was added by protocol amendment after the 0.5 mg/kg cohort completed enrollment to evaluate dose effects more fully after vasogenic edema (VE) was observed on brain MRI in the phase 1 study. Each dose cohort was enrolled after the SMC had reviewed safety in the preceding cohort. The final assessment was at week 78.
Outcome measures. The Alzheimer's Disease Assessment ScaleCognitive subscale (ADAS-Cog) 14, 15 and Disability Assessment for Dementia (DAD) 16 scales were co-primary outcomes. The ADAS-Cog/12-item (score range 0 -80) and DAD scales (score range 0%-100%) were administered before the first treatment, at each treatment visit, and at week 78. Except for the prespecified analyses, ADAS-Cog results are reported for the standard 11-item scale (without delayed word list recall; range 0 -70) for comparability to other studies (ADAS-Cog/12-item scale results are presented in table e-1 on the Neurology ® Web site at www.
neurology.org). The Neuropsychological Test Battery (NTB) 17 and MMSE (range 0 -30) were evaluated at the same intervals as the primary measures, and the Clinical Dementia Rating-Sum of Boxes (CDR-SB; range 0 -18) 18 was administered every 6 months. In patients consenting to lumbar puncture, CSF was obtained before treatment and at week 52. CSF biomarkers were measured by sandwich ELISAs for total tau, 19 phospho-tau (P-tau181), 20 and A␤ 42 21 (with the 4G8 antibody replacing 3D6 to make it specific for A␤ X-42 ). Volumetric and safety MRI scans were performed before treatment, at week 6, and then at 13-week intervals through week 71. Exploratory MRI outcomes included change in whole brain and ventricular volumes from baseline to week 71 as measured by the boundary shift integral method.
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Statistical analysis. Prespecified. The primary efficacy analysis compared bapineuzumab to placebo within the 0.5, 1.0, and 2.0 mg/kg cohorts based on change from baseline through week 78 using a repeated measures (RM) linear mixed effects model in the mITT population. Model terms were included for baseline MMSE score stratum, the baseline value of the efficacy variable, treatment, time as a continuous variable, and the interaction between treatment and time. The mean response was assumed to progress linearly with time. The 0.15 mg/kg cohort was analyzed with the same model; however, analyses in this group were exploratory and not adjusted for multiple comparisons. Analyses were performed with SAS version 9.1.
Exploratory analyses. The prespecified model assumed a linear rate of change throughout the study. The treatment difference at week 78 was however of primary interest and therefore, exploratory analyses that did not assume a specific pattern of decline over time were conducted. Nonlinear decline was also apparent in some outcomes, cohorts, and treatment groups. The exploratory analyses included time (study visit) as a categorical rather than continuous variable in the RM model. This model estimates covariate-adjusted means for each group at each time point (with week 78 being of primary interest), taking into account all observed data at all time points from all subjects including those with missing data. In addition to baseline score, MMSE stratum, and treatment, since VE occurred with greater frequency in APOE ⑀4 carriers than noncarriers, the revised model also included terms for APOE ⑀4 carrier status and for the APOE ⑀4 carrier status by time, treatment, and treatment-bytime interaction. Given the small sample size of each cohort and lack of a clear efficacy dose response, the 4 cohorts were combined. Positive treatment differences for efficacy variables indicate less decline in the bapineuzumab group. Treatment differences with p values between 0.05 and 0.10 were considered trends. Reported p values were not adjusted for multiple comparisons.
Populations. The modified intent-to-treat (mITT) population included patients who received at least one dose of study drug and had one or more postbaseline, co-primary efficacy evaluations. The "completer" population was defined as patients who completed all 6 infusions and a week 78 efficacy assessment.
Sample size. This study was not designed or powered as an efficacy study. The sample size was calculated to ensure Ն80% probability of detecting an adverse event (AE) that occurred with a rate of at least 5% within a single bapineuzumabtreated dose cohort.
RESULTS Subject disposition. Patient disposition is summarized by treatment groups combined across the 4 dose cohorts (figure 1). Of 317 screened patients, 234 were randomized (124 bapineuzumab vs 110 placebo). All randomized patients received at least one dose of bapineuzumab or placebo and were included in the safety population. Among those randomized, 122 bapineuzumab and 107 placebo patients were included in the mITT population. The percentage of patients who had a week 78 assessment was similar (74% bapineuzumab vs 79% placebo; figure 1 (table 2) for the ADAS-Cog and DAD. The apparent differences between the modeled and observed data were partly explained by nonlinear decline evident in some cohorts and treatment groups. Given the possibility of treatment effects across the range of tested doses and limited power to detect treatment differences within individual cohorts, exploratory analyses combined all dose groups without assuming linear decline over time.
Exploratory analyses by overall treatment group. Treatment differences (␦) in the mITT population showed trends on the ADAS-Cog (␦ ϭ 2.3 [95% CI Ϫ0.3, 4.9], p ϭ 0.078; figure 2) and NTB (␦ ϭ 0.13 [95% CI Ϫ0.01, 0.28], p ϭ 0.068) but not other outcomes (e.g., DAD, figure 2). In the completer population, treatment differences were observed (figure 2) on the ADAS-Cog (␦ ϭ 4. MRI volumetric analyses. Exploratory MRI analyses in the mITT population showed no treatment differences in brain or ventricular volume change. APOE ⑀4 noncarriers showed 10.7 mL less brain volume loss in the bapineuzumab group compared with placebo (95% CI 3.4, 18.0; p ϭ 0.004). No difference in ventricular volume was noted. APOE ⑀4 carriers showed no treatment difference in brain volume; however, greater ventricular enlargement was observed in the bapineuzumab group compared with placebo (2.6 mL; 95% CI 0.2, 5.0; p ϭ 0.037).
Safety. Most patients reported AEs over the course of 18 months (94% bapineuzumab vs 90% placebo). The rate of AEs was higher for bapineuzumab (7.5 vs 5.7 events per patient), but over 90% were mild to moderate in severity. AEs reported in Ͼ5% of bapineuzumab patients and at a rate twofold higher than placebo included VE (9.7% vs 0%), back pain (12.1% vs 5.5%), anxiety (11.3% vs 3.6%), paranoia (6.5% vs 0.9%), vomiting (9.7% vs 3.6%), hypertension (8.1% vs 3.6%), weight loss (6.5% vs 1.8%), skin laceration (5.6% vs 2.7%), gait disturbance (5.6% vs 1.8%), and muscle spasm (5.6% vs 0.9%). Except for VE, AEs were not dose-related. Other potentially important AEs reported in Ͻ5% of bapineuzumab-treated patients but more frequently than with placebo included deep vein thrombosis (3.2% vs 0%), syncope (4.8% vs 1.8%), seizures (3.2% vs 0.9%), pulmonary embolism (0.8% vs 0%), and cataracts (4.0% vs 0.9%). With respect to the AEs listed above, only vomiting and gait disturbance occurred in temporal association with VE. Serious AEs were reported in 37 (30%) bapineuzumab-treated patients and 22 (20%) placebo patients. VE in the high-dose bapineuzumab group accounted for much of this difference. Three deaths occurred in bapineuzumab-treated subjects (one case each of AD progression, obstructive renal failure, and pneumonia after a thoracic aortic dissection). A fourth death (progression of AD) was reported in a bapineuzumab-treated subject after the 78-week treatment period. None of the deaths were considered treatment or VE-related by the respective investigators or the SMC. The deaths were not associated with APOE ⑀4 or dose. No deaths were reported in the placebo group. Vasogenic edema. VE was detected on MRI in 12/ 124 patients (9.7%) treated with bapineuzumab and in 0/110 (0%) with placebo. Ten of these cases were The p values are from 2-sided tests. Model estimates are from the RM linear model with change from baseline score as the response and with model terms for treatment group (bapineuzumab and placebo), baseline score, Mini-Mental State Examination score stratum, visit week as a continuous variable, and the week-by-treatment group interaction. No p values from the prespecified primary analyses (0.5, 1.0, and 2.0 mg/kg cohorts) were significant. The treatment differences in the 0.15 mg/kg cohort were considered exploratory, and the associated p values are uncorrected for multiple comparisons. Observed treatment difference includes all patients with a week 78 assessment whether or not they received all scheduled doses. A positive change from baseline represents improvement. A positive treatment difference indicates less clinical decline in the bapineuzumab-treated group. ADAS-Cog ϭ Alzheimer's Disease Assessment Scale-Cognitive subscale; DAD ϭ Disability Assessment for Dementia; mITT ϭ modified intent-to-treat; RM ϭ repeated measures; N ϭ number of subjects included in the model (mITT subjects); n ϭ number of subjects with week 78 data; SE ϭ standard error; CI ϭ confidence interval.
detected on MRI scans specified by the protocol, and 11/12 occurred after the initial or second dose of study drug. VE ( figure 3 ) appeared on the fluidattenuated inversion recovery MRI sequence with high signal intensity in the white matter, leptomeninges, or sulci, and was frequently associated with gyral swelling and cortical T2 hyperintensity in the adjacent cortex. Six cases reported no clinical symptoms. In symptomatic patients, the most common AEs reported within 1 month of VE detection on MRI were headache, confusion, vomiting, and gait disturbance. One patient required treatment with dexamethasone. After cessation of dosing, these symptoms generally resolved over several weeks, while the MRI findings resolved over several months. VE increased with increasing bapineuzumab dose; VE rates were 3.2% for 0.15 mg/kg, 0% for 0.5 mg/ kg, 10.0% for 1.0 mg/kg, and 26.7% for 2.0 mg/kg. Eleven of the 12 VE cases occurred at doses Ն1.0 mg/kg. Ten of the 12 VE cases occurred in APOE ⑀4 carriers with a higher rate observed in APOE ⑀4 carriers (13.5%; 10/74) than noncarriers (4.3%; 2/47). VE increased with APOE ⑀4 gene dose, with VE rates of 4.3% (2/47) in patients with 0 copies of the allele, 7.1% (4/56) with 1 copy, and 33.3% (6/18) with 2 copies. Redosing was instituted in 6/12 patients starting at 0.15 mg/kg and titrating up to 50% of the originally assigned dose. No recurrence of VE has been observed to date in these patients.
DISCUSSION
This clinical trial explored the longterm safety and efficacy of bapineuzumab for the treatment of AD. The relatively low discontinuation rate during the 18-month study demonstrates that IV administration of serial doses of bapineuzumab is feasible and generally well-tolerated. The prespecified within-dose cohort analyses did not demonstrate significant treatment differences. Exploratory analyses with all dose cohorts combined showed favorable trends on the ADAS-Cog and NTB in the mITT population, while completer analyses showed differences on these endpoints and the DAD. We also found possible differences by APOE ⑀4 carrier status. In noncarriers, potential treatment differences favoring bapineuzumab were observed on some clinical measures. No treatment differences were demonstrated in APOE ⑀4 carriers. A number of reasons might account for these findings: first, greater efficacy was found in subjects who completed the study and a greater proportion of noncarriers were completers; second, more advanced A␤ pathology in APOE ⑀4 carriers 23 may have affected the clinical response; finally, the differences observed in these exploratory analyses could be due to chance.
The development of VE primarily at higher doses and in APOE ⑀4 carriers suggests that carriers be evaluated at a lower dose range in future studies. The etiology of VE is unknown but may be related to vascular amyloid burden. Amyloid deposition in cerebral blood vessels is more extensive in APOE ⑀4 carriers than noncarriers. 23 VE can occur spontaneously with cerebral amyloid angiopathy 24, 25 and with agents that alter vascular permeability, e.g., some cases of posterior reversible encephalopathy syndrome. 26, 27 VE may result from transient increases in vascular permeability associated with A␤ removal from cerebral blood vessels, or other mechanisms related to amyloid clearance. 28 VE resolved on MRI after discontinuation of bapineuzumab and was generally manageable with careful monitoring and dose adjustment. Other than VE, no major safety concerns were found. The deaths in the bapineuzumab group were not considered treatment related and were within the expected range for an 18-month AD study of this size. [29] [30] [31] The reduction in brain volume loss observed in the APOE ⑀4 noncarriers, relative to the placebo group, paralleled the clinical differences observed and may indicate slowing of brain atrophy. In carriers, no treatment-related difference in brain volume was observed. The cause and meaning of the increase in ventricular volume is uncertain. The trend toward reduced CSF phospho-tau 181 , a potential indicator of neurofibrillary pathology, 32 may suggest downstream effects of bapineuzumab on tau pathology similar to those seen with anti-A␤ immunotherapy in other studies, 7, 33, 34 but requires replication. This trial had several limitations. The sequential recruitment of small dose cohorts to evaluate safety, and the variable rate of decline in the treated and placebo groups within cohorts, restricted the statistical power to demonstrate efficacy and assess dose response. The prespecified linear model, motivated by the supposition that divergent slopes might argue for disease modification, lacked consistency with some of the observed data. VE and its relationship to APOE ⑀4 status and dose were not anticipated and This 69-year-old woman is an APOE ⑀4 homozygote who was treated with bapineuzumab 1.0 mg/kg IV. She remained asymptomatic despite the appearance of multiple areas of VE evident on the MRI. The VE was apparent on MRI by 7 weeks after her first infusion and resolved by 19 weeks. The patient was redosed at 0.5 mg/kg of bapineuzumab IV and followed for over 2 years without recurrence of VE.
limited treatment exposure in some patients. The exploratory analyses attempted to circumvent some of these limitations by 1) combining dose cohorts to increase sample size; 2) relaxing the assumption of linear disease progression; 3) assessing potential treatment differences by APOE ⑀4 status; and 4) evaluating results separately in completers. The exploratory efficacy analyses were not prespecified or controlled for multiple comparisons. These results must therefore be interpreted cautiously and require replication in more definitive trials. This limited phase 2 trial did not demonstrate efficacy on its primary outcomes, but exploratory analyses found potential treatment differences in completers and APOE ⑀4 noncarriers. These preliminary findings support continued evaluation of bapineuzumab for AD in phase 3 with consideration to possible treatment differences by APOE ⑀4 carrier status.
